Shots: J&J’s Ad26 vector-based vaccine demonstrated robust immune response in the pre-clinical study by neutralizing Abs, preventing infection and provide complete/ near-complete protection in the lungs from the virus in […]readmore
Tags : P-I/IIa
Shots: The focus of the study is to evaluate safety and tolerability profile of the combination of BI-1206 with Keytruda, characterizing PK/PD profile and to determine the recommended dose of […]readmore
Shots: Janssen has accelerated the initiation of the P-I/IIa study of its investigational Ad26.COV2-S recombinant vaccine. Earlier, the company had scheduled the clinical trial to begin in Sept’2020, the trial […]readmore
Shots: In July’2019, Bioinvent reports the FDA’s acceptance of its IND application of BI-1206 + Keytruda combination therapy based on the preclinical data demonstrating that BI-1206 enhances anti-tumor immune responses […]readmore